Most practitioners order a comprehensive metabolic panel, a lipid panel, thyroid labs, and maybe inflammatory markers. Few order a DEXA scan or grip strength assessment. Yet research in gerontology consistently shows that muscle mass, independent of body fat and standard metabolic risk factors, is inversely associated with all-cause mortality in older adults. The tissue most predictive of how long a patient will live is the tissue least assessed in preventive care.
Dr. Datis Kharrazian and the Kharrazian Institute (KI) train practitioners to recognize skeletal muscle not as a cosmetic concern or a fitness variable, but as a primary longevity organ with endocrine, metabolic, and immune functions that decline measurably with age. That reframe changes both the questions practitioners ask and the interventions they prioritize.
Why Muscle Mass Qualifies as a Longevity Organ
Skeletal muscle constitutes roughly 40 percent of total body mass in healthy adults. It is the body's largest glucose disposal site, a critical driver of basal metabolic rate, and an active endocrine tissue that secretes signaling proteins called myokines. When muscle contracts, it releases IL-6, irisin, BDNF, FGF-21, and other myokines that communicate with the liver, adipose tissue, brain, pancreas, and immune system. Muscle contraction is, in effect, a systemic anti-inflammatory signal.
This is why sarcopenia — the progressive, age-associated loss of skeletal muscle mass and function — carries consequences that extend far beyond mobility. Research in gerontology and metabolic medicine demonstrates that sarcopenia is associated with insulin resistance, increased inflammatory burden, compromised immune regulation, and higher all-cause mortality. It is not simply a consequence of getting old. It is a condition with pathophysiology that can be assessed, slowed, and in some cases partially reversed.
Dr. Kharrazian's clinical teaching emphasizes this distinction: muscle loss is not an inevitable backdrop to aging but a modifiable clinical variable that practitioners in functional medicine are positioned to address.
The Timeline of Sarcopenia: When Assessment Should Begin
Muscle loss begins earlier than most patients expect. Research indicates measurable decline in skeletal muscle mass starts around age 30, with losses accelerating after 60. Men may lose approximately 30 percent of their total muscle mass over their lifetime. Women experience similar trajectories, particularly following menopause, when the anabolic influence of estrogen diminishes.
The clinical implication is straightforward: waiting until a patient presents with falls, frailty, or obvious functional decline means missing a 30-year window of meaningful intervention. Preventive assessment should begin in the fourth decade, not the seventh.
The standard clinical tools — body weight and BMI — are inadequate here. A patient can maintain stable body weight while losing muscle and gaining adipose tissue simultaneously, a phenomenon called sarcopenic obesity. BMI will not detect it. A patient can appear metabolically normal on standard labs while their muscle mass has declined significantly. Assessment requires tools that actually measure muscle: DEXA-based lean mass analysis, bioelectrical impedance, appendicular skeletal muscle index, or at minimum, validated functional measures like grip strength and the timed up-and-go test.
Anabolic Resistance: Why Aging Patients Respond Differently to the Same Stimulus
In younger adults, protein intake and resistance exercise reliably stimulate muscle protein synthesis. With aging, that responsiveness diminishes. The muscles become less sensitive to the anabolic signals generated by dietary protein and mechanical load — a condition called anabolic resistance.
The mechanisms are several. Chronic low-grade inflammation, characteristic of aging (and referred to in the literature as "inflammaging"), impairs mTOR signaling pathways involved in muscle protein synthesis. Insulin resistance at the muscle level reduces glucose uptake and blunts anabolic signaling. Mitochondrial dysfunction reduces the energy available for muscle repair. Declining anabolic hormones — testosterone, IGF-1, DHEA, growth hormone — remove key cofactors in the synthesis process.
This is clinically important because it means that the protein dose and exercise stimulus required to produce the same anabolic result in a 65-year-old is higher than in a 35-year-old. Practitioners who apply the same protein recommendations across age groups are not accounting for the physiology. Research synthesized in Dr. Kharrazian's coursework highlights that older adults often require protein intakes well above standard recommendations to overcome anabolic resistance and adequately stimulate muscle protein synthesis.
What Does Adequate Protein Intake Actually Mean for Aging Patients?
The standard RDA for protein — 0.8 grams per kilogram of body weight per day — was established to prevent deficiency, not to optimize muscle maintenance in aging adults. Research in protein metabolism and sarcopenia consistently demonstrates that this level is insufficient for patients over 60 who are trying to preserve or rebuild muscle mass.
Current evidence supports intakes in the range of 1.2 to 1.6 grams per kilogram per day for older adults, with some research supporting higher amounts in the context of resistance training or recovery from illness. Beyond total quantity, the distribution of protein across meals matters. Research on muscle protein synthesis shows that a minimum threshold of leucine per meal is required to activate mTOR and initiate synthesis — typically 2.5 to 3 grams of leucine per meal. A patient eating most of their protein at dinner is not stimulating synthesis optimally across the day, regardless of total daily intake.
Protein quality also enters the clinical picture. Animal-source proteins are more leucine-dense and more bioavailable than most plant sources. This does not mean plant-based eating is incompatible with muscle maintenance, but it does mean that patients following plant-forward diets need targeted guidance to meet leucine thresholds — not a generic statement that their diet is "high in protein."
Inflammaging and the Musculoskeletal System: The Bidirectional Relationship
Inflammaging — the chronic, low-grade, sterile inflammatory state that accumulates with aging — both accelerates muscle loss and is worsened by muscle loss. The relationship is bidirectional and, if unaddressed, self-reinforcing.
Elevated circulating cytokines, particularly TNF-α and IL-6 in the context of chronic disease rather than acute muscle contraction, activate ubiquitin-proteasome pathways that break down muscle protein faster than it can be replaced. Adipose tissue, particularly visceral fat, is a significant source of these pro-inflammatory signals, which is one mechanism by which sarcopenic obesity is particularly damaging to muscle. Meanwhile, the loss of muscle-derived myokines removes an endogenous anti-inflammatory signal, allowing inflammatory burden to increase further.
This cycle matters for the functional medicine practitioner because many of the chronic patients who cannot recover — the ones presenting with fatigue, brain fog, metabolic dysregulation, and poor treatment response — are often running high inflammatory loads that are simultaneously degrading their muscle tissue. Addressing inflammaging is not separable from addressing sarcopenia in this population. Dr. Kharrazian's clinical training addresses these overlapping mechanisms and teaches practitioners to assess both simultaneously rather than treating them as separate clinical problems.
Practical Assessment and Clinical Strategy for Muscle Mass Preservation
Assessment should precede protocol. Before recommending protein targets or exercise programming, practitioners need to know where the patient currently stands. Appendicular skeletal muscle index (ASMI) from DEXA is the gold standard for identifying sarcopenia. Grip strength — measured with a hand dynamometer — is one of the strongest functional predictors of mortality in the literature. Gait speed and the sit-to-stand test provide additional functional data without requiring specialized equipment.
Once baseline is established, the clinical strategy addresses four areas concurrently:
- Protein quantity and distribution: Target 1.2 to 1.6 g/kg/day with leucine-threshold meals spread across the day. Adjust upward for patients with anabolic resistance or active inflammatory burden.
- Resistance exercise specificity: Muscle protein synthesis requires mechanical load. Aerobic activity alone does not stimulate the mTOR pathway adequately. Resistance training prescription should be specific, progressive, and individualized to the patient's functional capacity.
- Inflammatory burden reduction: Identify and address upstream drivers of inflammaging — intestinal permeability, adipose-driven cytokine production, metabolic endotoxemia, poor glycemic control, and any active autoimmune activity.
- Hormonal and micronutrient adequacy: Vitamin D, magnesium, omega-3 fatty acids, and creatine each have supporting research in muscle protein synthesis and anti-sarcopenic effects. Declining anabolic hormones warrant assessment and, where appropriate, clinical intervention.
The practitioner who assesses muscle mass alongside standard preventive labs is working with a fuller picture of patient longevity risk. The practitioner who ignores it is optimizing half the equation.
Key Takeaways
- Skeletal muscle functions as an endocrine organ, producing myokines that regulate immune, metabolic, and neurological function. Sarcopenia is not purely a mobility issue.
- Muscle mass, independent of body fat and standard metabolic markers, is inversely associated with all-cause mortality — making it a direct longevity variable worth assessing in clinical practice.
- Anabolic resistance in aging patients means standard protein recommendations are likely insufficient. Intake of 1.2 to 1.6 g/kg/day, with attention to leucine thresholds per meal, is better supported by current evidence.
- Inflammaging and sarcopenia are bidirectionally linked. Reducing inflammatory burden is part of any effective anti-sarcopenic protocol, not a separate clinical task.
- Assessment tools — DEXA-based ASMI, grip strength dynamometry, gait speed — should be incorporated into preventive evaluations beginning in the fourth decade, not when frailty is already present.
Frequently Asked Questions
Research in gerontology shows that skeletal muscle mass, independent of body fat and standard metabolic risk factors, is inversely associated with all-cause mortality in older adults. Higher muscle mass correlates with lower mortality risk, both through direct metabolic effects and through the endocrine activity of muscle-derived myokines that regulate inflammation and immune function.
Measurable muscle mass decline begins around age 30, with losses accelerating significantly after 60. Preventive assessment should begin in the fourth decade. Waiting for clinical frailty means missing decades of intervention opportunity. Tools include DEXA-based appendicular skeletal muscle index, grip strength dynamometry, and functional movement assessments.
Research consistently shows the standard RDA of 0.8 g/kg/day is insufficient for older adults managing sarcopenia. Evidence supports 1.2 to 1.6 g/kg/day, distributed across meals to meet per-meal leucine thresholds of approximately 2.5 to 3 grams, which are required to activate muscle protein synthesis through the mTOR pathway.
Inflammaging is the chronic, low-grade inflammatory state that accumulates with aging. Elevated TNF-α and IL-6 activate protein degradation pathways in muscle faster than synthesis can compensate. Simultaneously, muscle loss removes the anti-inflammatory myokine signal, worsening inflammatory burden. Addressing inflammaging is an essential component of any sarcopenia protocol.
Aerobic exercise provides cardiovascular and metabolic benefits but does not adequately stimulate the mTOR pathway required for muscle protein synthesis. Resistance training, providing progressive mechanical load, is necessary for preserving and rebuilding skeletal muscle mass in aging adults. Both forms of exercise contribute to longevity outcomes but address different mechanisms.
About the Author
Dr. Datis Kharrazian, PhD, DHSc, DC, MS, MMSc, FACN is a Harvard Medical School research fellow and researcher at Massachusetts General Hospital Department of Neurology specializing in autoimmunity and neuroimmunology. He serves as Associate Clinical Professor at Loma Linda University School of Medicine and is the author of Why Do I Still Have Thyroid Symptoms When My Lab Tests Are Normal and Why Isn't My Brain Working. He holds the designations of Fellow of the American College of Nutrition, Diplomate of the Board of Nutrition Specialists, member of the American Association of Immunologists, and Fellow of the Royal Society of Medicine (UK). The Kharrazian Institute serves more than 5,000 physicians and healthcare providers worldwide.
Continue Your Clinical Training
The Kharrazian Institute offers evidence-based practitioner training on functional assessment, chronic disease management, and the clinical strategies covered in this article. Visit the KI course catalog to find programs relevant to your practice.
